The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Abstract

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

Keywords

Affiliated Institutions

• University of California, Berkeley US
• Rhode Island Hospital US
• Inserm FR
• Johns Hopkins Medicine US
• Bristol-Myers Squibb (United States) US
• University of Virginia US
• University College London GB
• Mayo Clinic in Florida US
• University of California, San Diego US
• Alzheimer's Association US
• National Institute on Aging US
• Brown University US
• Johns Hopkins University US
• Institut du Cerveau FR
• Washington University in St. Louis US
• Mayo Clinic in Arizona US
• Prevent Alzheimer’s Disease 2020 US
• WinnMed US

Related Publications